Literature DB >> 21789902

Potential role of CCND1 G870A genotype as a predictor for urothelial carcinoma susceptibility and muscle-invasiveness in Taiwan.

Hui-Hui Lin1, Hung-Lung Ke, Kuang-Hung Hsiao, Chia-Wen Tsai, Wen-Jeng Wu, Da-Tian Bau, Lin-Li Chang.   

Abstract

The cell cycle regulator cyclin D1 (CCND1) is thought to play a major role in the transition of cell cycle from G1 to S phase. It is known that a common CCND1 G870A genotype is associated with bladder cancer in Japan and China, but not in the Western World. There is neither a report about its role in Taiwan's population, nor its genetic role of CCND1 G870A in another worldwide urothelial cancer, upper tract urothelial cancer (UTUC). Therefore, we aimed at investigating the role of CCND1 G870A in both bladder cancer and UTUC in Taiwanese cohorts. The CCND1 G870A genotypes of 171 (101 bladder cancer and 70 UTUC) patients and 243 control subjects were determined by PCR-RFLP and their correlation with clinical and histopathological data was evaluated. The genotype analysis results showed that CCND1 GG genotype was associated with a lower risk overall in urothelial (P = 0.008, OR = 0.44, 95% CI = 0.24-0.81) and bladder cancer patients (P = 0.008, OR = 0.34, 95% CI = 0.15-0.76) than those of the AA genotype. In addition, patients carrying the AG genotype had a 0.29-fold lower odds ratio of muscle-invasive cancer procession (95% CI = 0.12-0.70) compared with those carrying the AA genotype in bladder cancer patients. Surprisingly, the GG genotype had a 5.88-fold higher odds ratio of muscle-invasive cancer procession (95% CI = 1.08-32.01) compared with those carrying the AA genotype in UTUC. No association between any CCND1 G870A genotype and higher-grade risk was found. Our results suggest that the G allele of the CCND1 G870A polymorphism may be a potential predictive and prognostic biomarker to distinguish between bladder cancer and UTUC in Taiwan.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21789902     DOI: 10.4077/cjp.2011.amm123

Source DB:  PubMed          Journal:  Chin J Physiol        ISSN: 0304-4920            Impact factor:   1.764


  6 in total

1.  The CCND1 G870A polymorphism and susceptibility to bladder cancer.

Authors:  Jing Li; Fei Luo; Hongtuan Zhang; Liang Li; Yong Xu
Journal:  Tumour Biol       Date:  2013-07-28

2.  Association between CCND1 and XPC polymorphisms and bladder cancer risk: a meta-analysis based on 15 case-control studies.

Authors:  Yifei Wang; Zongping Li; Naibo Liu; Guan Zhang
Journal:  Tumour Biol       Date:  2013-11-22

3.  The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo.

Authors:  Tao Zhang; Peng Guo; Yinan Zhang; Hui Xiong; Xiao Yu; Shan Xu; Xinyang Wang; Dalin He; Xunbo Jin
Journal:  Int J Mol Sci       Date:  2013-12-18       Impact factor: 5.923

4.  Contribution of personalized Cyclin D1 genotype to triple negative breast cancer risk.

Authors:  Liang-Chih Liu; Chen-Hsien Su; Hwei-Chung Wang; Wen-Shin Chang; Chia-Wen Tsai; Ming-Chei Maa; Chang-Hai Tsai; Fuu-Jen Tsai; Da-Tian Bau
Journal:  Biomedicine (Taipei)       Date:  2014-08-27

Review 5.  Systematic Review: Genetic Associations for Prognostic Factors of Urinary Bladder Cancer.

Authors:  Nadezda Lipunova; Anke Wesselius; Kar K Cheng; Frederik J van Schooten; Jean-Baptiste Cazier; Richard T Bryan; Maurice P Zeegers
Journal:  Biomark Cancer       Date:  2019-12-30

Review 6.  Upper urinary tract disease: what we know today and unmet needs.

Authors:  Romain Mathieu; Karim Bensalah; Ilaria Lucca; Aurélie Mbeutcha; Morgan Rouprêt; Shahrokh F Shariat
Journal:  Transl Androl Urol       Date:  2015-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.